Next Post

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, […]